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ttp://dx.doi.org/10.1016/j.jmoldx.2012.12.004Bloodstream infections (BSIs) caused by bacteria and fungi are associated with signiﬁcant morbidity
and mortality. Currently, blood culture is the gold standard for conﬁrming a suspected BSI, but has the
drawback of lengthy time-to-detection (TTD) required for indicating the presence of microbes. Detec-
tion of conserved microbial nucleic acid sequences within blood culture samples via PCR has been
demonstrated to offer potential for reducing the TTD of BSI; however, these approaches have various
other limitations. We report a novel approach toward rapid detection of microbes from simulated BSI via
differential hematopoietic cell lysis followed by enzymatic template generation and ampliﬁcation
(ETGA)emediated measurement of microbial DNA polymerase extension activity. The differential cell
lysis procedure effectively reduced the level of detectable DNA polymerase extension activity associated
with human-derived hematopoietic cells present in blood culture samples taken from healthy donors.
After treatment with the differential cell lysis procedure, the ETGA assay detected a panel of clinically
prevalent bacteria and Candida albicans from spiked blood culture samples. The ETGA blood culture
method also reduced by threefold the TTD required for simulated BSI, compared with a continuous-
monitoring blood culture instrument. In summary, these ﬁndings demonstrate the feasibility of an
innovative approach toward a rapid, sensitive, and universal screen for microbes within blood culture
samples. Potential for clinical application and automation are also addressed. (J Mol Diagn 2013, 15:
319e330; http://dx.doi.org/10.1016/j.jmoldx.2012.12.004)Disclosures: All authors are employed by and the work was funded by
ZEUS Scientiﬁc, Inc.Bloodstream infections (BSIs) are a global problem associated
with serious health risks and hospital costs.1e8 Once BSI is
suspected, the clinical microbiologist plays a key role in
managing patient care by i) conﬁrming the presence of
a microorganism in a patient’s blood, ii) determining its Gram
status, and iii) subculturing the causative microorganism for
subsequent identiﬁcation and antimicrobial susceptibility
procedures.9e12 Currently, blood culture is an essential tool for
conﬁrming a suspected BSI and is ﬁrmly established as the
industry gold standard.13e17 However, even modern blood
culture systems still require 1 to 2 days of incubation to detect
the presence of most microbes,11,17,18 and so also represent
a rate-limiting step by delaying the initiation of critical
downstream testing, such as organism identiﬁcation andstigative Pathology
.antimicrobial susceptibility procedures. Because delays in
organism identiﬁcation and antimicrobial susceptibility
determination have been linked to decreased patient survival
and increased health care costs,5,6,19,20 reducing time-to-
detection (TTD) for BSI has potential to improve patient
outcomes.21 Consequently, numerous nucleic acid and none
culture-based rapid microbial detection methods have been
developed in an effort to reduce the TTD for BSI and subse-
quent administration of effective antimicrobial agents.22e24 To
date, however, various drawbacks have limited the widespread
adoption of such methodologies.25 For example, the so-called
Zweitzig et aluniversal PCR assays have been criticized, based on studies
revealing that the sequences targeted by the primers are not
actually universal.26e28
A pressing need therefore remains for an assay that can
rapidly and sensitively detect any microorganism present in
a blood culture sample. Such an assay could improve patient
outcomes by expediting the initiation of subsequent micro-
biological testing, thus decreasing the overall time until
appropriate therapy is administered. Because 90% of all
suspected BSI cultures yield negative results, another
important advantage of reduced TTD for BSI would be to
predict the true negative blood cultures earlier than the
current gold standard does, which could reduce the time and
costs of unnecessary hospital stays and facilitate improved
antimicrobial stewardship.
Our research group is actively developing assays based on
the enzymatic template generation and ampliﬁcation (ETGA)
methodology.29 We recently reported the initial character-
ization of a novel ETGA methodology, termed DNA poly-
merase extensionepolymerase chain reaction (DPE-PCR),
which enables sensitive, quantitative, and universal detection
of viable microbes.29 In the present study, our objective was
to determine the feasibility of using ETGA to detect the
presence of microorganisms within spiked blood culture
samples via measurement of their endogenous DNA poly-
merase activity. Considering that blood culture samples
contain vast numbers of DNA polymeraseeharboring
hematopoietic cells (HCs), each sample theoretically has the
potential to contribute signiﬁcant background signal to the
current version of the ETGA assay. Consequently, we set out
to determine whether a differential cell lysis procedure could,
when combined with ETGA, enable detection of microbes by
selective measurement of their DNA polymerase activity
within blood culture samples. To our knowledge, the meth-
odology and its application reported here represent an inno-
vative approach toward improved TTD of BSI.
Materials and Methods
Blood Collection from Healthy Donors
Blood (8 to 10 mL) was drawn from consenting healthy
donors into BD BACTEC Plus Aerobic/F bottles (catalog
no. 442192; BD Diagnostics, Sparks, MD). For the healthy-
donor screen used for establishment of the model system
positivity threshold, blood (5 mL) was also drawn into
a parallel EDTA tube (catalog no. 1172785; BD Diagnos-
tics), which was sent to LabCorp (Raritan, NJ) for complete
blood count analysis.
Differential Cell Lysis Procedure
We adapted a differential cell lysis procedure using detergent
and alkali, based on previous studies that demonstrated the
ability of such reagents to effectively lyse HCs without nega-
tively affecting microbes.30e32 An overview of the ETGA320blood culture assay protocol is presented in Supplemental
Figure S1. First, a 0.75-mL aliquot was removed from the
blood culture bottle, using a 21-gauge needle, and was trans-
ferred to a 1.5-mL tube already containing 250 mL of 1%Triton
X-100 detergent. The sample tube was then capped and
inverted four times, for mixing. The samplewas incubated for 5
minutes at room temperature and then centrifuged at 8000 g
for 3 minutes. The supernatant was poured off into a waste
container, and the tube was then inverted onto a plastic-backed
labwipe, to drain any residual liquid. Using an extended pipette
tip, 1 mL of 5 mmol/L NaOH was added and subsequently
pipetted up and down 10 times, to resuspend blood debris. The
sample tube was then capped, incubated for 5 minutes at room
temperature, and centrifuged at 8000  g for 3 minutes. The
supernatant was poured off into a waste container, and the tube
was then inverted onto a plastic-backed lab wipe, to drain any
residual liquid. Next, 0.6 mL of wash buffer (20 mmol/L Tris,
10mmol/L ammonium sulfate, 10mmol/L potassium chloride,
2 mmol/L magnesium sulfate) was added and pipetted up and
down ﬁve times, to resuspend the sample, and was simulta-
neously transferred to a prelabeled bead-mill lysis tube. At this
stage, 0.6 mL of wash buffer was added to an additional bead-
mill tube, which served as the no-input control. Next, 0.6mL of
wash buffer was added to an additional bead-mill tube, which
served as the DNA polymerase control. All bead-mill lysis
tubes were then centrifuged at 8000  g for 3 minutes.
Supernatants were carefully removed, using a 1-mL pipette.
After the supernatant had been aspirated, the samples were
transitioned to the core ETGA assay, as described below.
The Core ETGA Assay
Complete details regarding the composition of the core
ETGA assay (including DNA substrate and primer and probe
sequences) have been reported previously.29 Brieﬂy, 50 mL
of DNA polymerase extension (DPE) reaction mixture (50
mmol/L dNTP, 20 mmol/L Tris pH 8.0, 10 mmol/L ammo-
nium sulfate, 10 mmol/L potassium chloride, 2 mmol/L
magnesium sulfate, 1% bovine serum albumin, 0.1% Triton
X-100, 0.1% Tween 20, and 0.001 mmol/L preannealed DNA
substrate) was added to bead-mill tubes containing either
a processed blood culture sample or a no-input or DNA
polymerase control sample. Bead-mill tubes containing the
DPE reaction mixture were placed into a disrupter adapter
(Scientiﬁc Industries, Bohemia, NY) and were vortexed for 6
minutes at 2800 rpm. After this milling, 5 mL of DNA
polymerase (prediluted to a concentration of 1 107 U/mL;
catalog no. M0209S; New England Biolabs, Ipswich, MA)
was added to the designated DNA polymerase control tube;
all tubes were immediately transferred to 37C for 20
minutes, then to 95C for 5 minutes. After the 95C incu-
bation, tubes were cooled to room temperature and centri-
fuged at 12,000  g for 30 seconds. Four microliters of each
reaction was subsequently placed into a SmartCycler reaction
tube (Cepheid, Sunnyvale, CA) containing 27.2 mL of
a qPCR master mix, resulting in a mixture comprised ofjmd.amjpathol.org - The Journal of Molecular Diagnostics
ETGA Blood Culture Assay1 LightCycler 480 master mix (from 2 stock; catalog no.
04707494001; Roche Applied Science, Indianapolis, IN),
333 nmol/L of forward and reverse primers, 166 nmol/L
detection probe (FAM), 166 nmol/L internal control probe
(Texas Red), 1.2 U of uracil DNA glycosylase (catalog no.
BIO-20744; Bioline, Taunton, MA), and 40 copies of
a competitive internal control DNA. Thermal cycling was
performed using a SmartCycler II instrument (Cepheid) as
follows: initial incubation at 40C for 10 minutes and 50C
for 10 minutes and at 95C for 5 minutes, followed by 45
cycles of denaturation at 95C for 5 seconds and annealing
and extension at 65C for 20 seconds. CT values were
generated automatically by the SmartCycler software version
3.0b (Cepheid) using second-derivative analysis of the
emerging qPCR curves.
Detection of HC-Derived DNA Polymerase Activity via
ETGA
Because erythrocytes were not suspected to contain DNA
polymerases and are an established source of DNA poly-
merase inhibitors,33 we used serum separation tube (SST)
fractionation to deplete erythrocytes from HCs before being
subjected to ETGA assay analysis. First, 3-mL samples of
whole blood from two healthy donors were each aseptically
transferred from an EDTA tube to an SST (catalog no.
367988; BD Diagnostics). The SSTs were centrifuged at
2000  g for 10 minutes. The plasma supernatant was then
aspirated, and the erythrocyte-depleted HCs were gently
resuspended from the surface of the gel plug with 1 mL of
PBS. Each HC suspension was transferred to a new tube, the
volume was raised to 4 mL with PBS, and the tube was
centrifuged at 3000  g for 3 minutes. The supernatant was
removed, the HC pellets were resuspended in 1 mL of PBS,
and the volume was raised to 4 mL with PBS. This proce-
dure was repeated twice, for a total of three washes in
a volume of 4 mL. From each washed sample, 0.75 mL was
added to two bead-mill tubes. The bead-mill tubes were
centrifuged at 8000  g for 3 minutes, and the supernatant
was carefully aspirated down to the top of the bead bed.
Samples were subsequently processed according to the core
ETGA assay protocol procedure described above.
Because ddCTP has been previously demonstrated to
block DNA polymeraseedependent extension of the ETGA
assay substrate,29 we decided to substitute ddCTP for dCTP
in parallel DPE reactions containing HC lysates. Accord-
ingly, the paired samples from each donor were subjected to
DPE reactions with either a standard deoxynucleotide
triphosphate mix (dATP, dCTP, dGTP, and dTTP) (catalog
no. NO446S; New England Biolabs) or with a modiﬁed
deoxynucleotide triphosphate mix, in which ddCTP was
substituted for dCTP (ie, dATP, ddCTP, dGTP, and dTTP).
The no-input and DNA polymerase controls were run in
parallel. After the ETGA assay analysis, the samples were
also analyzed for the presence of HC-derived genomic DNA
using a BRAF qPCR assay, as described below.The Journal of Molecular Diagnostics - jmd.amjpathol.orgReduction of HC-Derived ETGA Assay Signal via the
Differential Cell Lysis Procedure
Two aliquots of whole blood (3 mL each from a single healthy
donor) were each transferred from EDTA tubes into two SSTs.
From each SST, HC suspensions were harvested, washed, and
pooled into a total of 8 mL. Next, 0.75-mL aliquots of the HC
suspensionwere placed into six sterile 1.5-mL tubes containing
0.25 mL of 1% Triton X-100. Three of these tubes were
immediately spiked with approximately 1000 CFU of Staph-
ylococcus aureus; the other three were not spiked. These six
samples were subsequently subjected to differential cell lysis
and ETGA analysis as described above. Three additional pre-
washed 0.75-mL aliquots of the HC suspension were placed
into bead-mill tubes and were processed in parallel, using only
the core ETGA assay, to provide nonlysed comparators. The
appropriate assay controls were included, as described above.
After the ETGA assay analysis, the lysates were also measured
for the presence of S. aureus genomic DNA, using a gene-
speciﬁc qPCR assay (gsPCR) as described below.
Description of gsPCR Assays
A human genomic DNA assay was designed from the Homo
sapiens v-raf murine sarcoma viral oncogene homolog B1
(BRAF). BRAF oligonucleotide sequences were as follows:
forward primer 50-TTGCCAGCTATCACATGTCC-30, re-
verse primer 50-TAACCCAGGCTAACCGACTG-30, and
hydrolysis probe 50-/56-FAM/TG CCTGTGTTTGCAGGT-
GAGAAGTTG/3IABkFQ/-30. A Candida albicansespeciﬁc
assay was designed against a yeast 18S rRNA sequence. The
C. albicansespeciﬁc oligonucleotide sequences were as
follows: forward primer 50-TTTATCAACTTGTCACACC-
AG-30, reverse primer 50-ATCCCGCCTTACCACTACCG-30,
and hydrolysis probe 50-/56-FAM/TGAACGCACATTG-
CGCCCTC/3IABkFQ/-30. All oligonucleotides were manu-
factured by Integrated DNATechnologies (Coralville, IA). The
PCRs were prepared as follows: 300 nmol/L forward and
reverse primers, 100 nmol/L hydrolysis probe, 12.5 mL
LightCycler 480 probes master mix (catalog no. 04902343001;
Roche Applied Science), nuclease-free water (catalog no.
AM9932; Life TechnologieseInvitrogen, Carlsbad, CA) to
a volume of 21 mL, and 4 mL of sample to be analyzed. The
samples were analyzed on a SmartCycler II instrument
(Cepheid) using the following protocol: 95C for 5 minutes,
and then 45 cycles of 95C for 15 seconds followed by 60C
for 40 seconds. Optical data were collected during the 60C
stage of each cycle. The gsPCR assays targeted to the nuc gene
of S. aureus and the uidA gene of Escherichia coli were as
described previously.29
Spike, Recovery, and Detection of Gram-Positive and
Gram-Negative Bacterial Panels from Blood Culture
The species in our panel of Gram-positive and Gram-
negative bacteria were chosen based on their established321
Zweitzig et alprevalence among clinical blood culture isolates.24
A complete list of all microbial strains used, including the
source and growth conditions, is given in Supplemental
Table S1. For both Gram-positive and Gram-negative
bacterial spikes, blood was collected into a BD BACTEC
Plus Aerobic/F bottle from a consenting healthy donor, as
described above. After collection, the blood culture bottle
was placed into a BACTEC incubator (model 9050; here-
after referred to simply as BACTEC) for approximately
1 hour, until the dilution of the bacterial stocks were
completed. Bacterial strains were prepared as follows. With
the exception of Streptococcus pneumoniae, two or three
freshly grown colonies of each strain were inoculated into
5 mL of braineheart infusion broth and were incubated at
37C with shaking until an optical density at 600 nm
(OD600) of 1.0  0.2 (approximately 109 CFU/mL) was
reached. For S. pneumoniae, one or two freshly grown
colonies were removed from a blood agar plate and resus-
pended in 1 mL of PBS (approximately 106 CFU/mL). All
strains were diluted in PBS to an approximate target
concentration of 1000 CFU/mL before being spiked into
blood culture. After bacterial strains had been diluted to the
target concentration of 1000 CFU/mL, 0.75-mL aliquots
were removed from the blood culture bottle, using a sterile
syringe equipped with a 21-gauge needle, and were trans-
ferred to sterile 1.5-mL tubes. Ten microliters of each
bacterial stock (at 1000 CFU/mL) was immediately added to
individual 0.75-mL blood culture aliquots. For each bacte-
rial strain used, stocks were further diluted to 1 CFU/mL;
parallel plating of 100 mL was also performed, to verify
approximate bacterial input. Ten microliters of sterile PBS
(used to dilute each bacterial strain) was added to an addi-
tional 0.75-mL blood culture aliquot, to serve as a no-spike
control (NSC). After the addition of bacteria (or PBS alone
for the NSC), 250 mL of 1% Triton X-100 was added to
each sample. Tubes were subsequently capped and inverted,
and samples were subjected to the differential cell lysis and
ETGA assay procedures as described above.
Model System Threshold Establishment via ETGA Blood
Culture Assay Analysis of 15 Healthy Donors
Blood culture bottles from a total of 15 healthy donors were
collected as four separate sample sets: A, donors 1 to 4; B,
donors 5 to 8; C, donors 9 to 12; and D, donors 13 to 15.
Before aliquot removal, the BACTEC bottles were placed into
a BACTEC incubator for 1 to 2 hours, to enable collection
from additional donors and for assay setup.After samples from
all the donors had been collected, duplicate 0.75-mL aliquots
of blood culture were removed from each BACTEC bottle,
using a sterile 1-mL syringe equipped with a 21-gauge needle,
and the differential cell lysis and ETGA assay procedures were
performed immediately. After aliquot removal, the blood
culture bottles were replaced into the BACTEC incubator for
a routine 5-day period, to conﬁrm that the samples were
negative. The raw ETGA assay data from 15 healthy donors322was exported from the SmartCycler software and was reas-
sembled using Microsoft Excel 2007 software. Samples that
were assigned CT values (derived from duplicate ETGA blood
culture assay analysis of the 15 healthy donors) were used to
generate a model system threshold value, calculated as
thresholdZ (average CT)  (3 SD CT).
Time-Course Growth Monitoring of S. aureus, E. coli,
and C. albicans in Blood Culture via ETGA Blood Culture
Assay
For each strain tested, two blood culture bottles were
collected from a consenting healthy donor, as described
above. One bottle was designated for spiking of microbes; the
other bottle served as the NSC. The presence of microbial
growth versus time was subsequently assessed for both
spiked and donor-matched NSC blood culture bottles by
traditional blood culture TTD (using a BACTEC instrument),
ETGA blood culture assay, gsPCR, and traditional microbial
plating analysis, as follows. After collection, the blood
culture bottles were placed into a BACTEC incubator for
approximately 1 hour, during preparation of microbial stocks.
For C. albicans, two or three freshly grown colonies had been
inoculated the previous day into yeast mold broth and grown
overnight at 30C, resulting in a stock at approximately 108
CFU/mL. Bacterial stock cultures were grown as described
above and were diluted in PBS to an approximate stock
concentration of 1 CFU/mL before being spiked into blood
culture. For C. albicans, the culture was diluted in PBS to an
approximate stock concentration of 20 CFU/mL before being
spiked into blood culture. For each strain, 100 mL of stock
solution (at either 1 CFU/mL for bacteria or 20 CFU/mL for C.
albicans) was added to a blood culture bottle using a sterile
1-mL syringe equipped with a 21-gauge needle. Microbial
stocks were also plated, to verify the approximate input
levels. To serve as the NSC, 100 mL of the appropriate sterile
diluent was added to a parallel (donor-matched) blood culture
bottle. Spiked and nonspiked blood culture bottles were
inverted, to mix the solution, and duplicate 1-mL aliquots
were immediately removed and labeled as t Z 0.
For time-course analysis of bacterial spikes, the blood
culture bottles were subsequently placed into a BACTEC
incubator. Duplicate 1-mL aliquots were removed at 2, 4, 6,
and 8 hours and were stored at 4C overnight, to synchronize
sample preparation. For time-course analysis of C. albicans,
1-mL aliquots were removed at time 0, and the blood culture
bottles were returned to the BACTEC incubator. Duplicate
1-mL aliquots were subsequently removed at 6, 10, and
26 hours. After overnight storage at 4C, to synchronize
sample preparation, 0.75-mL portions of the time-course
aliquots were processed together according to the differen-
tial cell lysis and ETGA assay procedures. Each unprocessed
100-mL blood culture aliquot was also plated in parallel, to
monitor CFUs during the time-course incubation. gsPCRwas
performed on 4 mL of the ETGA assay lysates derived from
each of the time-course samples, as described above.jmd.amjpathol.org - The Journal of Molecular Diagnostics
ETGA Blood Culture AssayResults
Detection of DNA Polymerase Extension Activity from
Erythrocyte-Depleted HCs
Here, we propose a novel approach for rapid detection of
microbes from blood culture samples via differential cell
lysis followed by ETGA assay analysis, collectively referred
to as the ETGA blood culture assay. A schematic of this
approach is presented in Figure 1. Before acquiring and
testing blood culture samples, we initially chose to assess
the level of ETGA assay signal derived from DNA poly-
meraseeharboring HCs. The erythrocyte-depleted HC
fractions taken from two independent healthy donors yiel-
ded strong ETGA assay signals (Figure 2A). Next, we
wanted to conﬁrm that the ETGA assay signal obtained
from HCs was dependent on DNA polymerase extension
activity. To this end, ddCTP was substituted for dCTP
within the DPE reaction mixture. The substitution of ddCTP
for dCTP effectively blocked substrate extension and
reduced the ETGA assay signal derived from HCs to the
level of assay baseline noise (Figure 2A). qPCR analysis of
a human genomic DNA marker (BRAF ) was performed on
the same lysates as presented in Figure 2A and conﬁrmed
that equivalent amounts of nucleated HCs were present in
the ddCTP-containing DPE reactions (Figure 2B).
Selective Reduction of HC-Derived ETGA Assay Signal
Using the Differential Cell Lysis Procedure
By establishing that HCs contribute ETGA assay signal in
the absence of input microbes, we conﬁrmed that ourFigure 1 A novel approach for detecting microbes in blood culture samples v
The Journal of Molecular Diagnostics - jmd.amjpathol.orgproposed approach for detection of microbes relies on
effective removal of HC-derived DNA polymerase exten-
sion activity. Consequently, our next objective was to
determine whether the proposed differential cell lysis
procedure can selectively reduce the ETGA assay signal
derived from erythrocyte-depleted HCs while maintaining
a microbe-derived signal. To this end, an additional blood
sample was collected from a healthy donor, and erythrocyte-
depleted HC suspensions were prepared and subjected to
ETGA assay analysis as described above. Nonlysed HCs
were reproducibly detected by ETGA assay (Figure 2C), at
a level similar to that shown previously (Figure 2A).
However, after being subjected to the differential cell lysis
procedure, the ETGA assay signal derived from HC aliquots
was reduced to assay baseline noise (Figure 2C). ETGA
data obtained from triplicate 0.75-mL aliquots of nonlysed
and lysed HCs were used to generate a value for fold
reduction of the ETGA assay signal, calculated as 1 10 to
the power [(average CT of lysis  average CT of no-lysis)/
3.33] (Figure 2D).
In addition to effectively reducing ETGA assay signal
from HCs, our proposed differential cell lysis procedure must
also enable detection of clinically relevant microbes. To this
end, triplicate parallel 0.75-mL HC aliquots were spiked with
approximately 103 CFU of S. aureus and subjected to the
ETGA blood culture assay procedure. After being processed
by the ETGA blood culture assay, S. aureusecontaining HC
aliquots were easily distinguishable from the parallel non-
spiked HC suspensions (Figure 2C). gsPCR was also per-
formed on the ETGA lysates and conﬁrmed the presence and
absence of S. aureus in the spiked and nonspiked HC
aliquots, respectively (Supplemental Figure S2).ia differential cell lysis followed by ETGA assay analysis.
323
Figure 2 ETGA assay and qPCR analysis. A:
Erythrocyte-depleted HCs taken from two indepen-
dent blood donors were analyzed by the core ETGA
assay. The resultant assay curves indicate the level of
ETGA signal detected from these cells. Substitution
of ddCTP for dCTP within parallel DPE reaction mixes
blocks the generation of ETGA assay signal, thus
conﬁrming that the HC-dependent background
signal is indeed derived from DPE activity. B: qPCR
was performed for the human genomic DNA marker
BRAF, to verify that equivalent amounts of HCs were
present in the ddCTP-containing DPE reactions
shown in panel A. C: Representative ETGA curves
demonstrate that the proposed differential cell lysis
procedure dramatically reduces the ETGA assay
background signal derived from erythrocyte-
depleted HCs, while still enabling detection of
S. aureus. D: The average CT values obtained from the
triplicate non-spiked ETGA blood culture assay
preparations shown in panel C were used to deter-
mine the fold reduction of ETGA signal that was
achieved by the differential cell lysis procedure.
Zweitzig et alEstablishment of an ETGA Positivity Threshold
Next, we tested the ability of the differential cell lysis
procedure to prevent signiﬁcant detection of DNA poly-
merase extension activity from negative blood culture
samples. The primary goal of these experiments was
twofold: to verify that the differential cell lysis procedure is
effective at removing ETGA signal from blood culture
samples taken from healthy donors and to establish a model
system positivity threshold using the ETGA data obtained
from the healthy-donor screen. First, duplicate 0.75-mL
blood culture aliquots (removed from blood culture samples
obtained from 15 healthy donors) were separated into four
sample sets and processed using the ETGA blood culture
assay protocol. A range of low-level ETGA blood culture
assay background signals were detected from the 15 donors
analyzed (Figure 3, AeD). The raw data from all 30 ETGA
blood culture assay preparations were extracted from the
SmartCycler software, combined, and regraphed using
Microsoft Excel (Figure 3E). DNA polymeraseepositive
controls were also included for each of the four separate
ETGA blood culture assay runs, to verify equivalent
performance of the core ETGA assay reagents (Figure 3E).
After collection and assembly, we subsequently per-
formed statistical analysis of the ETGA blood culture assay
data obtained from healthy donors and established a model
system positivity CT of 35.24, which could be used as an
objective means for determining sample positivity in our
subsequent experiments (Figure 3E). After aliquot removal,
blood culture bottles from each of the 15 healthy donors
were returned to the BACTEC incubator for a routine 5-day
period, to verify they were not contaminated with microbes
during the collection procedure and/or sample aliquoting.
The corresponding complete blood cell counts and BAC-
TEC results obtained from the 15 healthy donors were also
obtained (Supplemental Table S2).324The ETGA Blood Culture Assay Protocol Enables
Detection of Gram-Positive and Gram-Negative
Bacteria Spiked into Blood Culture Samples
After determining that the ETGA blood culture assay was
effective at limiting signal from numerous blood donors, we
next wanted to verify that it enabled detection of a clinically
prevalent panel of Gram-positive andGram-negative bacteria.
After performingETGAblood culture assay analysis, all seven
Gram-positive bacteria in the panel were detected well above
the model system positivity threshold and were easily distin-
guishable from the NSC (Figure 4A). Signals obtained from
ETGA blood culture assay analysis of all six Gram-negative
bacterial strains were also well above the model system posi-
tivity threshold, proportionate to CFU input, and easily
distinguishable from the NSC (Figure 4C). CFU input in
relation to ETGA blood culture assay signal is presented in
Figure 4B for Gram-positive bacteria and in Figure 4D for
Gram-negative bacteria.
Independent experiments aimed at ETGA blood culture
assay-mediated detection of Gram-positive and Gram-
negative bacteria in blood culture aliquots were repeated
by a different operator and yielded very similar results. All
blood culture bottles were replaced into the BACTEC
incubator, and no growth was detected after a routine 5-day
period, conﬁrming that the samples were not contaminated
during the manipulations associated with blood collection
and aliquoting.Monitoring of S. aureus Time-Course Growth in Blood
Culture via the ETGA Blood Culture Assay
To assess the ability of the ETGA blood culture assay to
detect simulated BSI, we monitored the time-course growth
of clinically prevalent microbes spiked into blood culturejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 3 ETGA blood culture assay. AeD:
Duplicate blood culture aliquots derived from 15
healthy donors were separated into groups A to D
and were analyzed using the ETGA blood culture
assay. ETGA assay curves indicate the level of
background (Bkgd) signal obtained from the
various donors. E: The data obtained from ETGA
blood culture assay analysis of the 15 healthy
donors were reassembled using Microsoft Excel. An
ETGA blood culture assay model system positivity
threshold value was subsequently generated,
calculated as the average background CT minus
three times its SD.
ETGA Blood Culture Assaysamples obtained from healthy donors. The ﬁrst microor-
ganism chosen for growth monitoring was S. aureus.
Growth of S. aureus (spiked at 100 CFU per bottle) was
compared with an NSC bottle, as described under Materials
and Methods. The BACTEC instrument properly designated
the bottle spiked with S. aureus as positive, with a TTD of
12.17 hours (Figure 5A). The BACTEC instrument did not
detect growth within the donor-matched NSC bottle after
a routine 5-day incubation period (Figure 5B). In contrast,
ETGA blood culture assay analysis of 0.75-mL blood
culture aliquots detected the presence of S. aureus in
aliquots removed after only 2 hours of incubation, and with
decreasing CT values (representing increasing amounts of
S. aureus) at each subsequent time point (Figure 5A). ETGA
blood culture assay analysis of aliquots taken from the
donor-matched NSC bottle did not yield assay signal higher
than the positivity threshold, and the analysis was therefore
in overall agreement with the BACTEC negativity result
(Figure 5B). Parallel plating of the same blood culture time-
course aliquots conﬁrmed the presence of viable S. aureus,
correlated with the corresponding signals (Figure 5, A and
B), and conﬁrmed that the NSC bottle was free of culti-
vatable bacteria (Figure 5, C and D). Detectable quantities
(2 CFU) of S. aureus were present on the perimeter of the
2-hour plate (Figure 5C). gsPCR was performed on the
same lysates used to generate ETGA blood culture assay
data, which conﬁrmed the presence of S. aureus growth in
the spiked samples and its absence in aliquots derived from
the NSC bottle, respectively (Figure 5, E and F).
Monitoring of E. coli Time-Course Growth in Blood
Culture via ETGA Blood Culture Assay
The next microorganism used to simulate a BSI was E. coli.
Similar to the procedure for S. aureus, 100 CFU of E. coli
were spiked into a freshly obtained blood culture bottle, andThe Journal of Molecular Diagnostics - jmd.amjpathol.orggrowth was compared with a donor-matched NSC via our
four methodologies. The BACTEC instrument properly
designated the bottle spiked with E. coli as positive, with
a TTD of 12.5 hours (Figure 6A), and no growth was
detected in the donor-matched NSC bottle after a routine
5-day incubation period (Figure 6B). ETGA blood culture
assay analysis detected the presence of E. coli in aliquots
removed as early as 2 hours after inoculation, and with
decreasing CT values at subsequent time points (Figure 6A).
ETGA blood culture assay analysis of 0.75-mL aliquots
taken from the donor-matched NSC bottle did not yield
assay signal above the model system positivity threshold,
and the analysis was therefore in overall agreement with the
BACTEC result (Figure 6B). Parallel time-course plating
analysis indicated presence of viable E. coli, correlated well
with corresponding signals (Figure 6, A and B), and
conﬁrmed that the NSC bottle was free of cultivatable
bacteria (Figure 6, C and D). gsPCR analysis was performed
on the same lysates used for ETGA blood culture assay
analysis, which conﬁrmed the presence of E. coli in the
spiked samples and its absence in aliquots derived from the
NSC bottle (Figure 6, E and F).
Monitoring of C. albicans Time-Course Growth in Blood
Culture via ETGA Blood Culture Assay
In addition to assessments with bacteria, we felt it important
to assess whether the ETGA blood culture assay can detect
and monitor the growth of C. albicans spiked into a blood
culture sample. Previous reports have demonstrated that
simulated candidemia exhibits inconsistent blood culture
positivity and increased TTD when spiked at as much as
1000 CFU per bottle.34,35 Therefore, to minimize nonlinear
growth behavior for feasibility of growth monitoring, we
targeted 1000 CFU, which resulted in 2000 CFU of C.
albicans, which was spiked into a freshly obtained blood325
Figure 4 ETGA blood culture assay analysis of
bacterial spikes. A and C: ETGA curves for seven
Gram-positive (A) and six Gram-negative (B)
bacterial species spiked into blood culture aliquots
and processed in parallel with an NSC, using the
ETGA blood culture assay protocol. B and D: To
relate CFU input to ETGA CT values, the ETGA assay
data shown in panels A and C were used to graph
approximate CFU input for each of the Gram-
positive (B) and Gram-negative (D) bacterial
species. CFU values are listed above the bar for
each species.
Zweitzig et alculture bottle. Growth was compared with a donor-matched
NSC via our four methodologies. The BACTEC instrument
properly designated the blood culture bottle spiked with
2000 CFU of C. albicans positive, with a TTD of 21 hours
(Figure 7A). Again, no growth was detected by the BAC-
TEC instrument in the donor-matched NSC bottle after
a routine 5-day incubation period (Figure 7B). The ETGA
blood culture assay was able to detect the presence of C.
albicans above the positivity threshold at time 0 (likely
because of the high inoculation level), and effectively
monitored its growth at subsequent time points (Figure 7A).
Once again, ETGA blood culture assay analysis of 0.75-mL
aliquots taken from the donor-matched NSC bottle did not
yield assay signal above the model system positivity
threshold, and the analysis was therefore in overall agree-
ment with the BACTEC result (Figure 7B). Parallel time-
course plating of blood culture aliquots (Figure 7, C and
D) demonstrated that the presence of viable C. albicans326CFU correlated well with the corresponding ETGA assay
signals in (Figure 7, A and B) and conﬁrmed the absence of
C. albicans growth within the NSC bottle. Parallel gsPCR
analysis of the same ETGA blood culture lysates also
conﬁrmed the presence of C. albicans genomic DNA in
aliquots taken from the spiked bottle and its absence within
the NSC bottle (Figure 7, E and F).
Assembly of Microbial Time-Course Growth Data
ETGA blood culture assay and gsPCR data obtained from of
S. aureus, E. coli, and C. albicans growth monitoring
experiments (Figures 5, 6, and 7) were subsequently
assembled into tabular format. For ETGA blood culture
assay analysis, a positive or negative call was assigned to
each sample result, using the model system positivity
threshold as a guide. For gsPCR, using the SmartCycler
software, a positive or negative call was assigned to eachFigure 5 Time-course ETGA data analysis (S.
aureus). A: CFU input, resultant ETGA curves, and
BACTEC TTD for time-course aliquots taken from
a blood culture bottle spiked with S. aureus and
analyzed by the ETGA blood culture assay. B: ETGA
curves and BACTEC results for the parallel time-
course analysis from a donor-matched NSC bottle.
C and D: Parallel plating was performed, using
0.1 mL from each of the time-course blood culture
aliquots, for both spiked (C) and donor-matched
NSC (D) blood culture bottles. E and F: qPCR
curves. S. aureusespeciﬁc qPCR analysis was per-
formed on the same lysates used to generate the
time-course ETGA data presented in panels A and B.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 6 Time-course ETGA data analysis (E.
coli). A: CFU input, resultant ETGA curves, and
BACTEC TTD for time-course aliquots taken from
a blood culture bottle spiked with E. coli and
analyzed by the ETGA blood culture assay. B: ETGA
curves and BACTEC results for the parallel time-
course analysis from a donor-matched NSC bottle.
C and D: Parallel plating was performed using
0.1 mL from each of the time-course blood culture
aliquots, for both spiked (C) and donor-matched
NSC (D) blood culture bottles. E and F: qPCR
curves. E. coliespeciﬁc qPCR analysis was per-
formed on the same lysates used to generate the
time-course ETGA data presented in panels A and B.
ETGA Blood Culture Assaysample result on the basis of the presence or absence of
a detectable ampliﬁcation curve. Complete time-course
results for each of the organisms tested are presented in
Table 1.Discussion
In the present study, we assessed the feasibility of using
ETGA methodology to detect the presence of microbes
within spiked blood culture samples via measurement of
endogenous microbial DNA polymerase activity. To our
knowledge, detection of microbes in blood culture via this
approach has not been attempted previously, and it thereforeThe Journal of Molecular Diagnostics - jmd.amjpathol.orgrepresents a novel methodology for rapid detection of BSI.
The fact that blood culture samples contain DNA polymer-
aseeharboring HCs, such as leukocytes and thrombocytes
(Figure 1), suggests an obvious theoretical barrier to detec-
tion of BSI via ETGA. We therefore ﬁrst conﬁrmed that
erythrocyte-depleted HCs represent a source of DNA poly-
meraseedependent background signal and must therefore be
controlled sufﬁciently to enable sensitive detection of
microbes via ETGA. Bearing in mind our previous ETGA
methodology characterization studies,29 we estimated that
the average CT value obtained from triplicate preparations of
lysed HCs (Figure 2D) is less than or equal to the CT value
that can be expected from a single bacterial CFU. Taken
together, these data suggested that the differential cell lysisFigure 7 Time-course ETGA data analysis (C.
albicans). A: CFU input, resultant ETGA curves, and
BACTEC TTD for time-course aliquots taken from
a blood culture bottle spiked with C. albicans and
analyzed by the ETGA blood culture assay. B: ETGA
curves and BACTEC results for the parallel time-
course analysis from a donor-matched NSC bottle.
C and D: Parallel plating was performed using
0.1 mL from each of the time-course blood culture
aliquots, for both spiked (C) and donor-matched
NSC (D) blood culture bottles. E and F: qPCR
curves. C. albicansespeciﬁc qPCR analysis was
performed on the same lysates used to generate
the time-course ETGA data in panels A and B.
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Zweitzig et alprocedure is effective at reducing the HC-dependent back-
ground signal, thus potentially enabling detection of low
amounts of microbes within a blood culture sample.
On a separate but relevant note, previous reports suggest
that monitoring DNA polymerase activity in HCs is of
clinical interest.36,37 The capability of the ETGA assay to
quantitatively measure DPE activity from nonlysed HCs
thus represents another potentially important research and/or
clinical utility for this methodology.
After demonstrating effective reduction of HC-derived
background signal, we assessed the ability of the ETGA
blood culture assay to detect a panel of clinically prevalent
bacteria. The results from these experiments demonstrated
that the ETGA signal from the spiked blood culture aliquots
was proportionate to CFU input and easily distinguishable
from nonspiked aliquots. These results further veriﬁed that




CT Result* CT Result
y
S. aureus
0 Hourseno spike 36.3 Neg ND Neg
2 Hourseno spike 37.9 Neg ND Neg
4 Hourseno spike 37.4 Neg ND Neg
6 Hourseno spike 36.1 Neg ND Neg
8 Hourseno spike 37.1 Neg ND Neg
0 Hoursespike 35.9 Neg ND Neg
2 Hoursespike 32.0 Pos 40.3 Pos
4 Hoursespike 28.5 Pos 36.1 Pos
6 Hoursespike 25 Pos 32.1 Pos
8 Hoursespike 19.1 Pos 26.5 Pos
E. coli
0 Hourseno spike 37.5 Neg ND Neg
2 Hourseno spike 36.8 Neg ND Neg
4 Hourseno spike 37.1 Neg ND Neg
6 Hourseno spike 36.7 Neg ND Neg
8 Hourseno spike 36.5 Neg ND Neg
0 Hoursespike 35.9 Neg ND Neg
2 Hoursespike 32.4 Pos 37.4 Pos
4 Hoursespike 30.1 Pos 37.8 Pos
6 Hoursespike 26.6 Pos 35.7 Pos
8 Hoursespike 20.9 Pos 30.8 Pos
C. albicans
0 Hourseno spike 36.7 Neg ND Neg
6 Hourseno spike 37.0 Neg ND Neg
10 Hourseno spike 36.7 Neg ND Neg
26 Hourseno spike 35.7 Neg ND Neg
0 Hoursespike 34.8 Pos ND Neg
6 Hoursespike 33.5 Pos 34.5 Pos
10 Hoursespike 32.0 Pos 33.8 Pos
26 Hoursespike 25.0 Pos 24.3 Pos
*ETGA positive is deﬁned as 35.24 CT.
ygsPCR positive is deﬁned as detectable CT by SmartCycler software.
ND, no CT determined by SmartCycler software; Neg, negative; Pos, positive.
328sufﬁcient to prevent signiﬁcant contribution of HC-derived
DNA polymerase activity, while still allowing ETGA-
mediated detection of clinically prevalent Gram-positive
and Gram-negative bacteria. These results also reinforced
the potential universality of our novel approach and, to our
knowledge, represent the ﬁrst example of detection of
bacteria from blood culture samples via measurement of
their endogenous DNA polymerase activity. Considered
together, the established sensitivity of the core ETGA
assay29 and the effective reduction of background signal
from HCs via differential cell lysis suggest that the ETGA
blood culture assay has the potential to enable more rapid
detection of microbes within blood culture samples,
compared with traditional blood culture methodology.
To test the feasibility of this hypothesis, we simulated BSI
and analyzed for positivity via four independent methodol-
ogies: i) traditional blood culture TTD using a BACTEC
instrument, ii) CFU plating, iii) gsPCR of genomic DNA, and
iv) ETGA blood culture assay time-course for TTD. S. aureus
(Gram-positive bacteria), E. coli (Gram-negative bacteria),
and C. albicans (yeast) were chosen for growth monitoring
experiments, because of their high prevalence among clinical
BSI isolates.8,24,38 The BACTEC TTD values obtained from
our simulated bacterial BSIs are similar to a range previously
determined from clinical samples39 and therefore support the
potential clinical translatability of our experimental conditions.
In contrast to the lengthyTTD for theBACTEC instrument, the
ETGA blood culture assay detected both S. aureus and E. coli
from sample aliquots taken after only 2 hours of incubation.
This result is also impressive from the perspective of bacterial
load, because our experimental inoculants represent a starting
bacterial concentration of approximately 2.5 CFU/mL in the
blood culture bottle, which simulates an original concentration
of approximately 10 CFU/mL of whole blood. Also, consid-
ering that up to 50%ofwhole blood samples frompatientswith
conﬁrmed BSI have been found to contain microbial concen-
trations of 10 CFU/mL,40 our data suggest that the ETGA
blood culture assay has the potential to reduce the BSI TTD
of clinical samples with similar microbial concentrations. A
gsPCR analysis performed with the same lysates used to
generate ETGA data conﬁrmed the presence and relative
amounts of S. aureus and E. coli in the simulated BSI samples
analyzed via ampliﬁcation of their genomicDNA.Furthermore,
these data also suggest that nucleic acidebased microbial
species identiﬁcation and resistance mechanism interrogation
can be performed subsequently to or simultaneously with the
ETGAblood culture assay analysis (providing that the bacterial
concentration of the analyzed blood culture aliquot is within the
limit of detection for the particular nucleic acidebased assay
being used). Because microbial identiﬁcation is required for
guiding optimal antimicrobial susceptibility testing, these data
further demonstrate the potential value added if the ETGA
blood culture assay were to eventually be integrated within
a routine clinical laboratory workﬂow.
Because BSI caused by Candida species are also
a signiﬁcant cause of patient morbidity and mortality,41 wejmd.amjpathol.org - The Journal of Molecular Diagnostics
ETGA Blood Culture Assayconsidered it important to address the feasibility of detecting
simulated BSI with C. albicans. Simulated candidemia has
been previously shown to exhibit inconsistent blood culture
positivity when spiked at approximately 1000 CFU per
bottle, and it can require extended incubation times.34,35 We
therefore we performed C. albicans spiking at slightly
greater than 1000 CFU per bottle, to minimize nonlinear
growth of C. albicans during feasibility studies. Although
our C. albicans CFU spike level is likely higher than what
would be observed from a typical clinical sample at the time
of draw, it still translates into only 60 CFU in the initial (tZ
0) 0.75-mL blood culture aliquot (conﬁrmed by plating)
(Figure 7C), thus suggesting that the ETGA blood culture
assay also has potential to detect the presence of fungi with
impressive sensitivity. ETGA blood culture assay lysates
also contained analyzable C. albicans genomic DNA, which
further demonstrates that our procedure is amenable also to
simultaneous and/or subsequent bacterial and fungal species
identiﬁcation using PCR-based methodologies.
In its current manual form, the entire ETGA blood culture
assay procedure requires approximately 2 hours turnaround
time to obtain a result. Thus, 2 hours must be added to the
amount of time each blood culture sample spends in the
BACTEC incubator before being aliquoted, to obtain a more
realistic ETGA TTD for comparison with the continuous-
monitoring blood culture system. Therefore, for the simulated
BSIs presented here, the actual ETGA TTD totaled 4 hours,
compared with the corresponding continuous-monitoring
blood culture TTD of approximately 12 hours, yielding
a threefold reduction in TTD. Considering the liquid handling,
centrifugation steps, and requirements of contamination
control, it would likely be difﬁcult to integrate the current
manual form of the ETGA blood culture assay procedure into
a busy clinical laboratory workﬂow. However, it is reasonable
to expect that the 2 hours required for the current nonoptimized
manual ETGA blood culture assay procedure could be cut in
half viaETGAautomation, inwhich lengthy centrifugation and
liquid handling steps could be replaced with more rapid
ﬁltration steps and with robotic manipulations. Automation of
ETGA could also control variations associated with human
manipulation and could provide random-access capabilities, all
of which could strengthen the potential for the ETGA assay to
be used as a BSI screening tool within a clinical setting. Once
BSI is conﬁrmed by ETGA, existing sample lysates could be
subsequently interrogated by nucleic acidebased assays for
species identiﬁcation and antimicrobial resistance mecha-
nisms, thus shortening the overall time required for initiation of
data-driven antimicrobial susceptibility testing and therapy.
In conclusion, we have demonstrated the feasibility of
a novel approach for detecting the presence of microbes
within spiked blood culture samples via selective measure-
ment of their DNA polymerase extension activity. The
collective data generated from our simulated BSI experi-
ments also strongly suggest that the ETGA blood culture
assay has the potential to reduce the TTD for clinical BSI
caused by either bacteria or fungi, compared with traditionalThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmethods. By detecting the presence of microbes via the
highly conserved biochemical activity of DNA polymerase
extension, the ETGA blood culture assay protocol poten-
tially represents a bona ﬁde universal microbe screening
method and could prove useful for rapidly detecting BSI
derived from a more diverse range of microbial species than
other methodologies, such as universal PCR assays (eg,
those that detect 16S rRNA sequences). Because ETGA
sample lysates also provide analyzable microbe-derived
nucleic acids, species identiﬁcation and antimicrobial
susceptibility mechanisms can be readily interrogated from
existing ETGA-positive samples. In addition to reduced
TTD of true BSI-positive blood cultures, the ETGA blood
culture assay has the potential to predict true BSI negatives
much earlier than current blood culture systems, thus
reducing the time and costs of unnecessary hospital stay. To
this end, we are currently planning to assess the perfor-
mance of the ETGA blood culture assay in a clinical setting.
We are also considering additional procedural and reagent
modiﬁcations aimed at detecting microbes directly from
whole blood. By eliminating the need for culture, such
modiﬁcations of the ETGA procedure could further reduce
the TTD of BSI.
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